Outcome of gestational trophoblastic disease in a rural tertiary centre of Haryana, India
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20164673Keywords:
Gestational trophoblastic disease, GTN, GTD, Molar pregnancy, NeoplasiaAbstract
Background: The reported incidence of GTD varies widely worldwide, from a low of 23 per 100,000 pregnancies (Paraguay) to a high of 1,299 per 100,000 pregnancies (Indonesia). The reported incidence of GTD in India is inconsistent therefore we planned to do an analysis of the GTD at our institute which is a referral tertiary center of Haryana.
Methods: Records of patients of GTD admitted from January 2014 to June 2016 were analyzed and incidence per 1000 deliveries was calculated. The demographic profile, clinical presentation, management and complications were studied.
Results: There were 38 patients of GTD with an incidence of 2.3 per 1000 deliveries. Out of 38 patients 33 (86.8%) were of molar pregnancy and 5 (13.16%) had GTN. Out of 33 molar patients 27 (81.8%) had complete mole and 6 (18.2%) had partial mole. All cases of GTN were low risk and received single agent methotrexate based chemotherapy. The mean age was 23.02±2.96 years and 47.4% were primigravida. The mean gestational age of presentation was 13.84 ± 3.24 weeks. There were no mortalities and no recurrences. Education in more than half i.e. 57.1% patients was below primary and 7 of the 19 patients with GTD, who could be followed telephonically, were found to have not followed the contraceptive advice and conceived within 6 months of the treatment of molar pregnancies, 5 had vaginal deliveries of live babies one of which was preterm and rest 2 had spontaneous abortions.
Conclusions: In view of poor reporting from developing countries there is a need for a nodal centre exclusively for GTD in each state. Poor compliance and contraceptive practice due to uneducated population especially in rural India, warrants a need for prophylactic chemotherapy in high risk cases.
References
Altieri A, Franceschi S, Ferlay J. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4(11):670-8.
Hinshaw K, Fayyad A, Munjuluri P. The managementof early pregnancy loss. In Green-top Guideline. London: Royal College of Obstetricians and Gynaecologists, 2006.
Newlands ES. Presentation and management of persistent gestational trophoblastic disease and gestational trophoblastic tumours in the UK. In: Hancock BW, Newlands ES, Berkowitz RS, Cole LA, editors. Gestational Trophoblastic Disease. 3rd ed. London: International Society for the Study of Trophoblastic Disease; 2003.p.277-298.
International Federation of Obstetrics and Gynecology Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynecol Obstet. 2002;77:285-7.
Seckl MJ, Sebire NJ, Fisher RA. Gol fier F, Massuger L, Sessa C, Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24(suppl 6):vi39-50.
Loukovaara M, Pukkala E, Lehtovirta P, Leminen A. Epidemiology of hydatidiform mole in Finland, 1975 to 2001. Eur J Gynaecol Oncol. 2005;26(2):207-8.
Garner EI, Goldstein DP, Feltmate CM, Berkowitz RS. Gestational trophoblastic disease. Clin Obstet Gynecol. 2007;50(1):112-22.
Shrivastava S, Gandhewar MR. Gestational trophoblastic disease: a profile of 37 cases. Int J Reprod Contracept Obstet Gynecol. 2014;3(2):317-20.
Humaira S, Gardezi AI, Qaisrani AR. Incidence of Molar Pregnancies at D. G. Khan Hospital. P J M H S. 2014;8(4):882-4.
Koirala A, Khatiwada P, Giri A, Kandel P, Regmi M, Upreti D. The Demographics of Molar Pregnancies in BPKIHS. Kathmandu University Medical Journal. 2011;9(4):298-300.
Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531-9.
Kumar N, Saxena KY, Rathi AK, Raghunandan C, Kumar P. Host and risk factors for gestational trophoblastic disease: a hospital-based analysis from India. Med Sci Monit. 2003;9(10):CR442-4.
Nirmala CK et al. Outcome of molar pregnancies in Malaysia: A tertiary centre experience. The Journal of Obstetrics and Gynaecology. 2013;33(2):191-3.
Sekl JM, Newlands ES. Gestational Trophoblastic Tumours. In: Shaw RW, Soutter WP, Stanton SL, editors. Gynecology. 3rd ed. Churchill Livingstone; 2003.p.653-654.
Ngan S, Seckl MJ. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol. 2007;19:486-91.
Burger RA, Creasman WT. Gestational Trophoblastic Neoplasia. In: Disaia PJ, Creasman WT, editors. Clinical Gynecology Oncology. 6th ed. Mosby; 2002.p.185-210.
Ekpo MD. Hyadatidiform Mole in Nigeria. Journal of Obstretrics and Gynecology. 1990;10:363-6.
Agrawal N, Sagtani RA, Budhathoki SS, Pokhare HP. Clinico-epidemiological profile of molar pregnancies in a tertiary care centre of Eastern Nepal: a retrospective review of medical records. Gynecologic Oncology Research and Practice. 2015[cited 4 November 2016];2:9
Hancock BW. Differences in management and treatment: a critical appraisal. In: Hancock BW, Newlands ES, Berkowitz RS, Cole LA, editors. Gestational Trophoblastic Disease. 3rd ed. London: International Society for the Study of Trophoblastic Disease; 2003.p.447-59.
Fu J, Fang F, Xie L. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database System Rev. 2012;10.
